These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19256507)

  • 1. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
    Man HW; Schafer P; Wong LM; Patterson RT; Corral LG; Raymon H; Blease K; Leisten J; Shirley MA; Tang Y; Babusis DM; Chen R; Stirling D; Muller GW
    J Med Chem; 2009 Mar; 52(6):1522-4. PubMed ID: 19256507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide analogs and PDE4 inhibition.
    Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
    Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
    Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T
    Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
    Gewald R; Grunwald C; Egerland U
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
    Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
    Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally active PDE4 inhibitor with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
    Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
    Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles.
    Stewart SG; Braun CJ; Ng SL; Polomska ME; Karimi M; Abraham LJ
    Bioorg Med Chem; 2010 Jan; 18(2):650-62. PubMed ID: 20034801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
    Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
    Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
    J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
    Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
    Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
    J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.